| Autor: |
Liu ES; CK Life Sciences International Inc., Tai Po Industrial Estate, Hong Kong. edgar.liu@ck-lifesciences.com, Luk SC, Leung ET, Lee WH, Yuen WF, Kwok KM, Siu SW, Kwok NS, Xing HT, Wu M, Pang SF |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of chemotherapy (Florence, Italy) [J Chemother] 2008 Apr; Vol. 20 (2), pp. 246-52. |
| DOI: |
10.1179/joc.2008.20.2.246 |
| Abstrakt: |
Prostate carcinoma and metastasis are common among male subjects worldwide. CKBM is a drug product targeting prostate cancer in multiple ways. Prostate cancer cell lines PC3 and DU145 were treated with CKBM. The effect of CKBM on the cell's viability, cell cycle, adhesive and invasive properties and its growth in an animal model were assessed. Results indicated that CKBM inhibited PC3 and DU145 cell growth in vitro at IC(50 )values 3.923 and 4.697% respectively, and it brought about cell cycle arrest at G2/M phase. CKBM also attenuated DU145 cells to invade and adhere to extracellular matrices including Matrigel, laminin, fibronectin and collagen IV. Moreover, PC3 tumor xenograft growth was inhibited by over 60% after 28-day of 0.2, 0.4 or 0.8 ml/day CKBM treatment. The present study indicates that CKBM is effective against prostate cancer cell growth in vitro and in vivo. Further studies are required to elucidate its mechanism of action. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
